The MALSU1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphoblast cell line, designed to disrupt the MALSU1 gene. This gene-edited product provides a loss-of-function model to investigate the role of MALSU1 in mitochondrial ribosome assembly and translation. The polyclonal format offers a heterogeneous population of knockout cells, suitable for pooled functional studies without clonal selection.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphoblast line originally established from a Burkitt lymphoma patient. These suspension-adapted cells are widely employed as a model system for B cell biology, apoptosis, and immune signaling. Their lymphoblastoid morphology and robust growth characteristics make them a valuable platform for studying mitochondrial function and metabolic regulation in lymphoid malignancies.
MALSU1 encodes a mitochondrial ribosomal protein assembly factor essential for the biogenesis of both the large and small mitochondrial ribosomal subunits. By enabling efficient mitochondrial translation, MALSU1 supports the synthesis of mtDNA-encoded oxidative phosphorylation (OXPHOS) subunits including MT-ND1, MT-CO1, and MT-CYB. Upstream regulators such as NRF1 and TFAM coordinate mitochondrial gene expression, while MALSU1 interacts with numerous mitochondrial ribosomal proteins (MRPs) to facilitate ribosome assembly. Knockout of MALSU1 disrupts mitochondrial translation, leading to impaired production of OXPHOS complexes I, III, IV, and V and a consequential decline in ATP synthesis via oxidative phosphorylation.
In the Raji B cell lymphoma background, MALSU1 knockout provides a unique tool to dissect the interplay between mitochondrial function and B cell biology. Given the reliance of rapidly proliferating lymphoma cells on mitochondrial metabolism, loss of MALSU1 may uncover mitochondrial vulnerabilities specific to B cell malignancies. This model enables studies into how mitochondrial translation defects influence apoptosis, metabolic reprogramming, and survival signaling in EBV-transformed B cells, thereby contributing to a deeper understanding of lymphomagenesis and potential therapeutic targets.
Researchers can employ these polyclonal knockout cells in functional assays such as oxygen consumption rate (OCR) measurement, JC-1 staining for mitochondrial membrane potential, and SUnSET-based detection of nascent mtDNA-encoded protein synthesis. Western blotting and RT-qPCR enable validation of MALSU1 disruption and quantification of downstream OXPHOS subunits. This tool is suited for mitochondrial dysfunction research, inhibitor screening, and metabolic reprogramming studies in cancer. For additional details or inquiries, please contact Ascent Research.
